HC Wainwright Forecasts Lower Earnings for Tyra Biosciences

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Equities researchers at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Tyra Biosciences in a research report issued on Wednesday, August 5th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.76) per share for the quarter, down from their previous forecast of ($0.70). HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($2.86) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.80) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.81) EPS and FY2027 earnings at ($3.20) EPS.

Several other equities research analysts have also issued reports on TYRA. JonesTrading assumed coverage on shares of Tyra Biosciences in a research report on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. Guggenheim initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They issued a “buy” rating and a $54.00 target price for the company. Wolfe Research started coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Finally, Bank of America increased their target price on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.90.

Tyra Biosciences Trading Up 4.9%

Shares of TYRA opened at $26.96 on Friday. Tyra Biosciences has a 12-month low of $9.96 and a 12-month high of $40.65. The company has a market cap of $1.61 billion, a PE ratio of -11.23 and a beta of 0.77. The stock has a 50-day moving average price of $30.18 and a 200-day moving average price of $32.70.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04).

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently made changes to their positions in the business. Hilton Head Capital Partners LLC purchased a new position in Tyra Biosciences in the 1st quarter worth $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $51,000. Chung Wu Investment Group LLC bought a new position in shares of Tyra Biosciences during the fourth quarter valued at about $53,000. State of Wyoming bought a new position in shares of Tyra Biosciences during the second quarter valued at about $76,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after buying an additional 534 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Key Headlines Impacting Tyra Biosciences

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $45 price target for Tyra Biosciences. The target remains well above the stock’s recent trading level, suggesting the firm sees potential upside based on the company’s longer-term pipeline prospects. Tyra Biosciences stock information
• Neutral Sentiment: Analysts continue to broadly support the shares: Tyra carries a consensus “Moderate Buy” recommendation. However, the stock remains unprofitable, with analysts expecting a loss of approximately $2.68 per share for the current fiscal year. Tyra Biosciences receives Moderate Buy consensus
• Negative Sentiment: HC Wainwright reduced its EPS estimates across late 2026 and 2027, including FY2026 to a loss of $2.86 per share from $2.74 and FY2027 to a loss of $3.20 from $3.09. Quarterly estimates were also lowered, indicating expectations for larger losses and potentially higher cash-burn risk. The revisions follow Tyra’s latest quarterly report, in which it posted a $0.69-per-share loss versus the $0.65 consensus estimate. Tyra Biosciences shares gap down after disappointing earnings

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.